上皮性卵巢癌中的血管生成
Angiogenesis in epithelian ovarian cancer.
作者信息
Bamberger E S, Perrett C W
机构信息
Department of Biology, University of Haifa at Oranim, Tivon 36006, Israel.
出版信息
Mol Pathol. 2002 Dec;55(6):348-59. doi: 10.1136/mp.55.6.348.
Abstract
Angiogenesis, the development of new blood vessels from the existing vasculature, is an essential component of solid tumour growth and metastasis. Several angiogenic factors are expressed by many tumours, suggesting that tumours promote their own vascularisation by activating the host endothelium. This review will discuss various angiogenic stimulators and inhibitors in epithelian ovarian cancer (EOC), including vascular endothelial growth factor and platelet derived endothelial cell growth factor/thymidine phosphorylase. The analysis of tumour vascularisation by microvessel density will also be discussed and the relevance of these markers of angiogenesis in the prognosis of EOC will be assessed.
摘要
血管生成，即从现有脉管系统发育出新的血管，是实体瘤生长和转移的重要组成部分。许多肿瘤都会表达多种血管生成因子，这表明肿瘤通过激活宿主内皮细胞来促进自身血管化。本综述将讨论上皮性卵巢癌（EOC）中的各种血管生成刺激因子和抑制因子，包括血管内皮生长因子和血小板衍生内皮细胞生长因子/胸苷磷酸化酶。还将讨论通过微血管密度分析肿瘤血管生成的情况，并评估这些血管生成标志物在EOC预后中的相关性。
相似文献
1
Angiogenesis in epithelian ovarian cancer.
Mol Pathol. 2002 Dec;55(6):348-59. doi: 10.1136/mp.55.6.348.
2
Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Oncol Rep. 2003 Jan-Feb;10(1):89-95.
3
4
Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
Int J Oncol. 2003 May;22(5):961-7.
5
The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
J Pathol. 2003 Jun;200(2):183-94. doi: 10.1002/path.1339.
6
Prognostic role of angiogenesis in colorectal cancer.
Anticancer Res. 2001 Nov-Dec;21(6B):4349-53.
7
Vascular endothelial growth factor expression in non-small cell lung cancer.
Methods Mol Med. 2003;74:357-73. doi: 10.1385/1-59259-323-2:357.
8
The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
Clin Cancer Res. 2002 Jun;8(6):1863-70.
9
VEGFs, angiopoietins, Ephrins and their receptors: putative targets for tumor therapy?
Ann Hematol. 2002;81 Suppl 2:S66.
10
[Expression of VEGF and tumor angiogenesis in bladder cancer].
Zhonghua Wai Ke Za Zhi. 2000 Jan;38(1):34-6.
引用本文的文献
1
Bacterial Extracellular Vesicles in Oncology: Molecular Mechanisms and Future Clinical Applications.
Cancers (Basel). 2025 May 26;17(11):1774. doi: 10.3390/cancers17111774.
2
The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model.
BMC Cancer. 2025 Feb 11;25(1):233. doi: 10.1186/s12885-025-13640-z.
3
Role of Cancer Side Population Stem Cells in Ovarian Cancer Angiogenesis.
Med Princ Pract. 2024;33(5):403-413. doi: 10.1159/000539642. Epub 2024 Jul 26.
4
The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities.
Curr Oncol. 2024 Jul 1;31(7):3826-3844. doi: 10.3390/curroncol31070283.
5
Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer.
J Ovarian Res. 2024 Jul 17;17(1):149. doi: 10.1186/s13048-024-01471-8.
6
Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.
Ther Adv Med Oncol. 2024 Feb 29;16:17588359241233225. doi: 10.1177/17588359241233225. eCollection 2024.
7
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.
Int J Mol Sci. 2024 Feb 3;25(3):1845. doi: 10.3390/ijms25031845.
8
The long non-coding RNA NEAT1 promotes the progression of human ovarian cancer through targeting miR-214-3p and regulating angiogenesis.
J Ovarian Res. 2023 Nov 20;16(1):219. doi: 10.1186/s13048-023-01309-9.
9
Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine.
Front Pharmacol. 2023 Mar 7;14:1147717. doi: 10.3389/fphar.2023.1147717. eCollection 2023.
10
Differential Expression of HIF1A, EPAS1, and VEGF Genes in Benign and Malignant Ovarian Neoplasia.
Cancers (Basel). 2022 Oct 7;14(19):4899. doi: 10.3390/cancers14194899.
本文引用的文献
1
Vascular endothelial growth-factor expression and angiogenesis in nonsmall cell lung carcinomas.
Int J Oncol. 1995 May;6(5):1059-62. doi: 10.3892/ijo.6.5.1059.
2
HETEROLOGOUS TRANSPLANTATION OF MAMMALIAN TUMORS : I. THE TRANSFER OF RABBIT TUMORS TO ALIEN SPECIES.
J Exp Med. 1941 Mar 31;73(4):461-74. doi: 10.1084/jem.73.4.461.
3
Pieces of eight: bioactive fragments of extracellular proteins as regulators of angiogenesis.
Trends Cell Biol. 1997 May;7(5):182-6. doi: 10.1016/S0962-8924(97)01037-4.
4
Angiogenesis as a biomarker and target in cancer chemoprevention.
Lancet Oncol. 2001 Dec;2(12):726-32. doi: 10.1016/S1470-2045(01)00586-1.
5
Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma.
Cancer Lett. 2002 Feb 8;176(1):111-8. doi: 10.1016/s0304-3835(01)00754-6.
6
Identification of an angiogenic mitogen selective for endocrine gland endothelium.
Nature. 2001 Aug 30;412(6850):877-84. doi: 10.1038/35091000.
7
Different features of angiogenesis between ovarian and breast carcinoma.
Cancer Lett. 2001 Sep 20;170(2):161-7. doi: 10.1016/s0304-3835(01)00588-2.
8
A new link in ovarian cancer angiogenesis: lysophosphatidic acid and vascular endothelial growth factor expression.
J Natl Cancer Inst. 2001 May 16;93(10):734-5. doi: 10.1093/jnci/93.10.734.
9
Angiogenesis in cancer and other diseases.
Nature. 2000 Sep 14;407(6801):249-57. doi: 10.1038/35025220.
10
Vascular-specific growth factors and blood vessel formation.
Nature. 2000 Sep 14;407(6801):242-8. doi: 10.1038/35025215.
Zotero 插件